OS Therapies Inc filed a Form D with the Securities and Exchange Commission on 2026-10-23.
OS Therapies Inc filed a Form D notice of an exempt securities offering with the SEC on October 23, 2026. The filing reports $7.17M sold. Its industry group is Biotechnology. It names Paul Romness (Chairman, President and Chief Executive Officer), Robert Petit (Chief Medical Officer and Chief Scientific Officer), Francis Knuettel II (Chief Financial Officer) (SEC Form D, October 23, 2026).
Sell to companies like OS Therapies Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns OS Therapies Inc.
Free to see. No signup.
More on the people and the money behind OS Therapies Inc, from the filings we hold.
Ceros Financial Services, Inc. received sales compensation on this raise and on 4 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Maryland, filed in October 2026, largest first.
Get an email when OS Therapies Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when OS Therapies Inc raises, hires or launches. No email unless you switch it on.
Watch OS Therapies Inc →Get the full cited report on OS Therapies Inc
What the filing shows about OS Therapies Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on OS Therapies Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for OS Therapies Inc →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $7.17M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Paul Romness is named as Chairman, President and Chief Executive Officer on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Robert Petit is named as Chief Medical Officer and Chief Scientific Officer on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Francis Knuettel II is named as Chief Financial Officer on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
John Ciccio is named as Director on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
Avril McKean Dieser is named as Director on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
Craig Eagle is named as Director on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
Olivier Jarry is named as Director on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
Theodore Search is named as Director on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Kerry Clem is named as Chief Commercial Officer on the Form D that OS Therapies Inc filed with the SEC on 23 October 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-10-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about OS Therapies Inc
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on OS Therapies Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OS Therapies Inc covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist OS Therapies IncYou get an alert in MentionFox the next time this company shows up.
If you're behind OS Therapies Inc: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-25 (ostherapies.com).
Each opens in a new tab, filled in for OS Therapies Inc. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-10-19 · Biotech raises, week of 2026-10-19
https://mentionfox.com/funding/os-therapies-inc-form-d-002846